Technical Analysis for OASM - Oasmia Pharmaceutical AB

Grade Last Price % Change Price Change
grade F 1.55 1.97% 0.03
OASM closed up 1.97 percent on Wednesday, August 21, 2019, on 3 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical OASM trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
180 Bearish Setup Bearish Swing Setup 1.97%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.97%
Wide Bands Range Expansion 1.97%
Oversold Stochastic Weakness 1.97%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.32%

Older signals for OASM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.
Chemistry Cancer Organic Compounds Cancers Chemotherapy Breast Cancer Ovarian Cancer Lymphoma Organic Chemistry Metastatic Breast Cancer Treatment Of Ovarian Cancer Treatment Of Breast Cancer Docetaxel Doxorubicin Paclitaxel Treatment Of Metastatic Breast Cancer Squamous Cell Carcinoma
Is OASM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 20 OASM LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of Important September 27th Deadline in Securities Class Action – OASM
Aug 20 INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Aug 19 Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Bronstein, Gewirtz & Grossman, LLC - Class Action Update
Aug 18 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm
Aug 16 Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) – Class Action Update - Bronstein, Gewirtz & Grossman, LLC
Aug 16 Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB – OASM
Aug 16 Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Class Action - Bronstein, Gewirtz & Grossman, LLC
Aug 14 Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
Aug 14 IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm
Aug 13 INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
See more OASM news...
Indicators
Indicator Value
52 Week High 5.7
52 Week Low 0.9381
Average Volume 292,516
200-Day Moving Average 2.5492
50-Day Moving Average 1.6702
20-Day Moving Average 1.6588
10-Day Moving Average 1.573
Average True Range 0.175
ADX 10.58
+DI 18.597
-DI 20.768
Chandelier Exit (Long, 3 ATRs ) 1.565
Chandelier Exit (Short, 3 ATRs ) 1.965
Upper Bollinger Band 1.9084
Lower Bollinger Band 1.4092
Percent B (%b) 0.28
BandWidth 30.094044
MACD Line -0.0684
MACD Signal Line -0.0533
MACD Histogram -0.0152
Fundamentals Value
Market Cap 89.32 Million
Num Shares 57.6 Million
EPS -0.49
Price-to-Earnings (P/E) Ratio -3.16
Price-to-Sales 51.73
Price-to-Book 0.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.58
Resistance 3 (R3) 1.58 1.58 1.58
Resistance 2 (R2) 1.58 1.57 1.58 1.57
Resistance 1 (R1) 1.56 1.56 1.56 1.56 1.57
Pivot Point 1.56 1.56 1.56 1.56 1.56
Support 1 (S1) 1.54 1.55 1.54 1.54 1.53
Support 2 (S2) 1.54 1.54 1.54 1.53
Support 3 (S3) 1.52 1.54 1.53
Support 4 (S4) 1.52